DNA topoisomerase II in therapy-related acute promyelocytic leukemia. Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, Parry A, Walz C, Wiemels JL, Segal MR, Adès L, Blair IA, Osheroff N, Peniket AJ, Lafage-Pochitaloff M, Cross NC, Chomienne C, Solomon E, Fenaux P, Grimwade D (2005) N Engl J Med 352: 1529-38 Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL (2007) J Clin Oncol 25: 493-500 Copy number polymorphisms and anticancer pharmacogenomics. Gamazon ER, Huang RS, Dolan ME, Cox NJ (2011) Genome Biol 12: R46 DNA topoisomerase IIalpha interacts with CAD nuclease and is involved in chromatin condensation during apoptotic execution. Durrieu F, Samejima K, Fortune JM, Kandels-Lewis S, Osheroff N, Earnshaw WC (2000) Curr Biol 10: 923-6 Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH (1997) Blood 90: 935-43 Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides. Duca M, Guianvarc'h D, Oussedik K, Halby L, Garbesi A, Dauzonne D, Monneret C, Osheroff N, Giovannangeli C, Arimondo PB (2006) Nucleic Acids Res 34: 1900-11 The geometry of DNA supercoils modulates the DNA cleavage activity of human topoisomerase I. Gentry AC, Juul S, Veigaard C, Knudsen BR, Osheroff N (2011) Nucleic Acids Res 39: 1014-22 The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Deweese JE, Osheroff N (2009) Nucleic Acids Res 37: 738-48 Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. Ando K, Shah AK, Sachdev V, Kleinstiver BP, Taylor-Parker J, Welch MM, Hu Y, Salgia R, White FM, Parvin JD, Ozonoff A, Rameh LE, Joung JK, Bharti AK (2017) Oncotarget 8: 43733-43751 Catalytic function of DNA topoisomerase II. Osheroff N, Zechiedrich EL, Gale KC (1991) Bioessays 13: 269-73 E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Nip J, Strom DK, Fee BE, Zambetti G, Cleveland JL, Hiebert SW (1997) Mol Cell Biol 17: 1049-56 Etoposide: four decades of development of a topoisomerase II inhibitor. Hande KR (1998) Eur J Cancer 34: 1514-21 Topoisomerase poisons: harnessing the dark side of enzyme mechanism. Froelich-Ammon SJ, Osheroff N (1995) J Biol Chem 270: 21429-32 Topoisomerase II from Chlorella virus PBCV-1 has an exceptionally high DNA cleavage activity. Fortune JM, Lavrukhin OV, Gurnon JR, Van Etten JL, Lloyd RS, Osheroff N (2001) J Biol Chem 276: 24401-8 Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast. Elsea SH, Osheroff N, Nitiss JL (1992) J Biol Chem 267: 13150-3 Inhibition of eukaryotic topoisomerase II by ultraviolet-induced cyclobutane pyrimidine dimers. Corbett AH, Zechiedrich EL, Lloyd RS, Osheroff N (1991) J Biol Chem 266: 19666-71 Base excision repair intermediates as topoisomerase II poisons. Wilstermann AM, Osheroff N (2001) J Biol Chem 276: 46290-6 A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine. Elsea SH, Hsiung Y, Nitiss JL, Osheroff N (1995) J Biol Chem 270: 1913-20 Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme. Corbett AH, Hong D, Osheroff N (1993) J Biol Chem 268: 14394-8 A two-drug model for etoposide action against human topoisomerase IIalpha. Bromberg KD, Burgin AB, Osheroff N (2003) J Biol Chem 278: 7406-12 A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines. Jensen LH, Nitiss KC, Rose A, Dong J, Zhou J, Hu T, Osheroff N, Jensen PB, Sehested M, Nitiss JL (2000) J Biol Chem 275: 2137-46 Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes. Cline SD, Osheroff N (1999) J Biol Chem 274: 29740-3 Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage. Fortune JM, Osheroff N (1998) J Biol Chem 273: 17643-50 Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Elsea SH, McGuirk PR, Gootz TD, Moynihan M, Osheroff N (1993) Antimicrob Agents Chemother 37: 2179-86 Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme. Froelich-Ammon SJ, McGuirk PR, Gootz TD, Jefson MR, Osheroff N (1993) Antimicrob Agents Chemother 37: 646-51 NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy. Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE (2014) Antimicrob Agents Chemother 58: 2657-64 Phosphorylation of Rad9 at serine 328 by cyclin A-Cdk2 triggers apoptosis via interfering Bcl-xL. Zhan Z, He K, Zhu D, Jiang D, Huang YH, Li Y, Sun C, Jin YH (2012) PLoS One 7: e44923 Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Wilstermann AM, Osheroff N (2003) Curr Top Med Chem 3: 321-38 Coordinating the two protomer active sites of human topoisomerase IIalpha: nicks as topoisomerase II poisons. Deweese JE, Osheroff N (2009) Biochemistry 48: 1439-41 DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition. Fortune JM, Velea L, Graves DE, Utsugi T, Yamada Y, Osheroff N (1999) Biochemistry 38: 15580-6 DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement. Byl JA, Fortune JM, Burden DA, Nitiss JL, Utsugi T, Yamada Y, Osheroff N (1999) Biochemistry 38: 15573-9 DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. Byl JA, Cline SD, Utsugi T, Kobunai T, Yamada Y, Osheroff N (2001) Biochemistry 40: 712-8 1,4-Benzoquinone is a topoisomerase II poison. Lindsey RH, Bromberg KD, Felix CA, Osheroff N (2004) Biochemistry 43: 7563-74 N-acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison. Bender RP, Lindsey RH, Burden DA, Osheroff N (2004) Biochemistry 43: 3731-9 Polychlorinated biphenyl quinone metabolites poison human topoisomerase IIalpha: altering enzyme function by blocking the N-terminal protein gate. Bender RP, Lehmler HJ, Robertson LW, Ludewig G, Osheroff N (2006) Biochemistry 45: 10140-52 Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement. Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N (2000) Biochemistry 39: 2726-32 Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions. Ketron AC, Denny WA, Graves DE, Osheroff N (2012) Biochemistry 51: 1730-9
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.